The eternal question in solid tumor oncology, almost Shakespearean in its persistence When is Cisplatin better than Carbo? When are they equivalent? Excited to share our new paper in @JAMANetworkOpen where we examined the certainty of evidence of the 11 major meta-analyses (12 683 pts) on which guidelines based their recommendations ✴️Several efficacy variables have low or very low level of certainty ✳️Only high-certainty evidence signal was found for Cis>Carbo in ORR urothelial, and the no PFS difference Cis=Carbo in ovarian. 🟡Despite high heterogeneity impacting GRADE across tumour types, toxicities show known correlations The story does not end here, highlighting the utility of meta-data appraisals and current evidence gaps. We might not need new trials, just greater access to data from completed studies #oncology @myESMO @ASCO 👏An honour to have worked with and learned from this faculty Prof Harrington @MattGalsky Prof Colombo @EnriquetaFelip Dr Rodon @juditsanz Dr Pereira @DrMirallas @OncoAlert @brunolarvol @OncBrothers